Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; maize starch; colloidal anhydrous silica; povidone - women: moderately severe to severe signs of androgenization. moderately severe/severe forms of hirsutism.moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization.cyproterone acetate inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.if androcur is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation.men:reduction of drive in sexual deviations androcur reduces the force of the sexual urge in men with sexual deviations. whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a pre-requisite for therapy is the desire by the patient for treatment.androcur therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation.inoperable prostatic carcinoma to suppress "flare" with initial lhrh analogue therapy in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide monohydrate, quantity: 1.069 g (equivalent: cyclophosphamide monohydrate, qty 1 g) - injection, powder for - excipient ingredients: - frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter's staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *modified as the international staging classification for hodgkin's disease in 'report of the committee on the staging of hodgkin's disease'. cancer res 26: 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or waldeyer's ring. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer's ring. all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms. frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung. immunosuppressive properties: cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide monohydrate, quantity: 534.5 mg (equivalent: cyclophosphamide monohydrate, qty 500 mg) - injection, powder for - excipient ingredients: - frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter's staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *modified as the international staging classification for hodgkin's disease in 'report of the committee on the staging of hodgkin's disease'. cancer res 26: 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or waldeyer's ring. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer's ring. all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms. frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung. immunosuppressive properties: cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10.5 mg (equivalent: metoclopramide hydrochloride, qty 10 mg) - tablet, uncoated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; lactose; magnesium stearate; microcrystalline cellulose - indications as at 18 december 2001: as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties (such as cytotoxic agents); uraemia, radiation sickness, malignant disease, post-operative vomiting, labour, infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide has been found useful in the management of gastric retention after gastric surgery; of diabetic gastroparesis of mild to moderate severity. once control of diabetes is established by diet and/or insulin, use of metoclopramide should be discontinued.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10.537 mg (equivalent: metoclopramide hydrochloride, qty 10 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch; magnesium stearate; maize starch - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - amidotrizoate meglumine, quantity: 660 mg/ml; sodium amidotrizoate, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: disodium edetate; anise oil; polysorbate 80; saccharin; purified water - gastrografin is a contrast medium for examination of the gastrointestinal tract. it can be administered orally and as enema and is primarily indicated in cases in which the use barium sulfate is unsatisfactory, undesirable or contraindicated. among these are: - suspected partial or complete stenosis - acute haemorrhage - threatening perforation (peptic ulcer, diverticulum) - other acute conditions which are likely to require surgery - after resection of the stomach or the intestine (danger of perforation or leak) - megacolon - visualisation of a foreign body or tumour before endoscopy - visualisation of gastrointestinal fistula. in addition to these conditions gastrografin can generally be used for the same purposes as barium sulfate with the exception of the visualisation of mucosal diseases. due to the insufficient coating properties of gastrografin, barium sulfate should be used for single or double contrast techniques. in combination with barium sulfate, gastrografin has considerably improved routine inve

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

farmalinx pty ltd - copper present as copper oxychloride; metalaxyl - wettable powder - copper present as copper oxychloride mineral-copper active 350.0 g/kg; metalaxyl phenylamide active 150.0 g/kg - fungicide - grapevine | macadamia nut - downy mildew on grape | phytophthora root rot | trunk and stem canker | phytophthora trunk rot | soil fungi

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kenso corporation (m) sdn. bhd. - soyal phospholipids; propionic acid - dispersible concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - adjuvant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - acidifying surfactant | improve drift control | penetrating surfactant | reduce alkaline hydrolysis | improves chemical uptake

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

grochem australia pty ltd - sulphur - water dispersible granule - sulphur mineral-sulphur active 800.0 g/kg - mixed function pesticide - citrus | grape - see label | grape - table | grape - wine | kiwi fruit | mangosteen | nectarine | ornamental | peach | plum | po - bean or broad bean rust- u. viciae-fabae | bean spider mite | black spot | blossom blight - botrytis spp. | brown citrus rust mite | brown rot | bud mite | citrus melanose | citrus rust mite or maori mite | grapeleaf blister mite | lichen | mite | moss | powdery mildew | rust | tomato russet mite | two spotted mite | vine mite | white louse scale | brown citrus mite | citrus rust mites | citrus snow scale | red spider mite | rust mite | scab | spider mite | tomato mite (47236) | two-spotted mite | two-spotted spider mite | uromyces phaseoli var. typica | vineleaf blister mite

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sanonda (australia) pty ltd - soyal phospholipids; propionic acid - soluble concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - surfactant - agricultural chemical additive | herbicide additive | wetting agent | activator | penetrant | post emergent herbicide | spray ac - reduce alkaline hydrolysis | tank mixing | wetting agent (use as directed) | additive | agricultural chemical | herbicide | improve penetrating properties | minimise antagonism | spray tank